Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Confirmatory Efficacy and Safety Trial of Magnetic Seizure Therapy for Depression

NCT: NCT03191058 · COMPLETED

NCT IDNCT03191058
StatusCOMPLETED
Start Date2018-06-26
Completion2024-11-22

Brief Summary

This trial aims to assess the efficacy and tolerability of Magnetic Seizure Therapy (MST) as an alternative to electroconvulsive therapy (ECT) for depression. Even with multiple medication trials, 30 - 40% of patients will experience a pharmacologically resistant form of illness. The ineffectiveness of current treatments for major depressive disorder (MDD) coupled with the economic burden associated with the disorder engenders a need for novel therapeutic interventions that can provide greater response and remission rates.

Frequently Asked Questions

What is Confirmatory Efficacy and Safety Trial of Magnetic Seizure Therapy for Depression?

Confirmatory Efficacy and Safety Trial of Magnetic Seizure Therapy for Depression is a clinical trial registered under NCT03191058. Current status: COMPLETED.

What is the status of NCT03191058?

The current status of NCT03191058 (Confirmatory Efficacy and Safety Trial of Magnetic Seizure Therapy for Depression) is: COMPLETED.

When did Confirmatory Efficacy and Safety Trial of Magnetic Seizure Therapy for Depression start?

Confirmatory Efficacy and Safety Trial of Magnetic Seizure Therapy for Depression started on 2018-06-26.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.